Evaluation of the Efficacy of Novel Biomarkers in Predicting Clopidogrel Resistance in Patients with Ischemic Stroke

Exclusion Criteria

• •72 hours after the onset of symptoms (admission), the patient began receiving "standard" antiplatelet therapy (including polivix, taken alone or in combination) for moderate or severe AIS (NIHSS score ≥ 5)
• •Patients who require intravenous thrombolysis (using rt PA, urokinase, alteplase, or tiniprase, etc.)
• •Mechanical intervention for thrombectomy
• •Cardiogenic AIS (with concomitant atrial fibrillation)
• •Embolic stroke of unknown origin (ESUS)
• •Perioperative stroke
• •Use anticoagulant drugs (such as warfarin, rivaroxaban, dabigatran etexils, etc.)
• •Individuals with severe liver and kidney dysfunction
• •Individuals allergic to clopidogrel or aspirin
• •Individuals with a tendency towards bleeding (such as low platelet count or active gastric or intestinal ulcers)
• •Individuals with a history of easy miscarriage or who are currently pregnant
• •Patients with malignant tumors or life expectancy of less than 1 year